ScholarIQanswers from OpenAlex & ORCID
Daichi Fujimoto
ResearcherPublications, citations & collaboration network
Daichi Fujimoto is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Daichi Fujimoto have?
ScholarIQindexed works
Daichi Fujimoto has 243 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Daichi Fujimoto have?
ScholarIQcitation count
Daichi Fujimoto has 4,081 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Daichi Fujimoto?
ScholarIQh-index
Daichi Fujimoto has an h-index of 35 in OpenAlex.
What is the i10-index of Daichi Fujimoto?
ScholarIQi10-index
Daichi Fujimoto has an i10-index of 82 in OpenAlex.
What is the ORCID of Daichi Fujimoto?
ScholarIQorcid
The ORCID for Daichi Fujimoto is on the source record.
What is the OpenAlex record for Daichi Fujimoto?
ScholarIQopenalex
The OpenAlex for Daichi Fujimoto is on the source record.
What are the most-cited papers on Daichi Fujimoto?
ScholarIQmost cited works
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Shunsuke Teraoka, Daichi Fujimoto, Takeshi Morimoto, Hayato Kawachi, Munehiro Ito, Yuki Sato, Kazuma Nagata, Atsushi Nakagawa, Kojiro Otsuka, Keiichiro Uehara, Yukihiro Imai, Kaori Shintani‐Ishida, Junya Fukuoka, Keisuke Tomii
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, Daichi Fujimoto, Motoko Tachihara, Naoki Furuya, Sakiko Otani, Junichi Shimizu, Nobuyuki Katakami, Koichi Azuma, Naoko Miura, Kazumi Nishino, Satoshi Hara, Shunsuke Teraoka, Satoshi Morita, Kazuhiko Nakagawa, Nobuyuki Yamamoto
“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
Emina Torlakovic, Hyun J. Lim, Julien Adam, Penny J. Barnes, Gilbert Bigras, Anthony W.H. Chan, Carol C. Cheung, Jin-Haeng Chung, Christian Couture, Pierre Fiset, Daichi Fujimoto, Gang Han, Fred R. Hirsch, Marius Ilié, Diana N. Ionescu, Chao Li, Enrico Munari, Katsuhiro Okuda, M. Ratcliffe, David L. Rimm, Catherine Ross, Rasmus Røge, Andreas H. Scheel, Ross A. Soo, Paul E. Swanson, Maria Tretiakova, Ka‐Fai To, Gilad W. Vainer, Hangjun Wang, Zhaolin Xu, Dirk Zielinski, Ming‐Sound Tsao
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Yoshiko Urata, Nobuyuki Katakami, Satoshi Morita, Reiko Kaji, Hiroshige Yoshioka, Takashi Seto, Miyako Satouchi, Yasuo Iwamoto, Masashi Kanehara, Daichi Fujimoto, Norihiko Ikeda, Haruyasu Murakami, Haruko Daga, Tetsuya Oguri, Isao Goto, Fumio Imamura, Shunichi Sugawara, Hideo Saka, Naoyuki Nogami, Shunichi Negoro, Kazuhiko Nakagawa, Yoichi Nakanishi
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori, Terufumi Kato, Shunichi Sugawara, Keisuke Kirita, Yasuto Yoneshima, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka, Takehito Shukuya, Ken Masuda, Hidetoshi Hayashi, Ryo Toyozawa, Satoru Miura, Daichi Fujimoto, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Toshiaki Takahashi